NASDAQ: CFRX Navigate ContraFect Corporation HOME ABOUT US TECHNOLOGY PIPELINE INVESTORS & MEDIA CAREERS CONTACT US Investor Relations Home Investors & Media Investor Relations Investors & Media OVERVIEW NEWS / EVENTS PRESENTATIONS COMPANY INFORMATION FINANCIAL INFORMATION ANALYST COVERAGE STOCK DATA SEC FILINGS CORPORATE GOVERNANCE Email Alerts Tear Sheet Contacts RSS News Feed LATEST NEWS ContraFect Reports Third Quarter 2021 Financial Results and Provides Corporate Update Nov 15, 2021 READ PRESS RELEASE LATEST FINANCIAL RESULTS Q3 2021 Quarterly Results Quarter Ended Sep 30, 2021 PDF HTML Release PDF HTML 10-Q Filing HTML Financials ZIP XLS HTML XBRL SIGN UP FOR EMAIL ALERTS Be the first to receive breaking news SIGN UP TODAY STOCK INFORMATION DATA IS 15 MINUTES DELAYED ContraFect Corporation — Common Stock NASDAQ: CFRX Price Change Market Cap Volume COMPANY OVERVIEW ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of direct lytic agents (DLAs), which include lysins and amurin peptides. We believe DLAs provide the opportunity to make meaningful improvements to clinical outcomes and to change the treatment paradigm for patients infected with antibiotic-resistant bacteria. Our initial product candidates are new agents to treat lethal, resistant infections such as methicillin-resistant Staph aureus (MRSA) and Gram-negative pathogens like multi-drug resistant (MDR) Pseudomonas aeruginosa. OFFICERS & DIRECTORS MANAGEMENT BOARD OF DIRECTORS ROGER J. POMERANTZ, M.D., F.A.C.P. President, Chief Executive Officer and Chairman of the Board Dr. Pomerantz has served as Chairman of our board of directors and our Chief Executive Officer since April 2019. Prior to that, he had served as Vice Chairman of our board of directors since May 2014. From November 2013 to Dece... VIEW FULL PROFILE » © 2021 ContraFect Corporation. All Rights Reserved. COPYRIGHT PRIVACY POLICY EXPANDED ACCESS POLICY DISCLAIMER SITE MAP LINKEDIN TWITTER